Abstract
The establishment of imatinib as the standard therapy for CML marked the beginning of a new era of treatment. Due to occurring intolerance and resistance against the drug, developing newer inhibitors was promoted. This led to the second-generation inhibitors dasatinib, nilotinib and bosutinib. Despite all achieved improvement, all first- and second-generation inhibitors are ineffective against the BCR-ABL T315I “gatekeeper” mutation. In order to overcome this issue and to further improve the inhibitory effect, the third-generation inhibitor ponatinib was developed. Various clinical trials have been launched to study the effect of ponatinib in the clinical setting. Based on positive phase 1 and phase 2 trials, ponatinib was approved for the second-line treatment of CML and Ph+ ALL in December 2012 in the United States and in July 2013 in the European Union. Further trials investigate the potential effect of ponatinib in kinase-dependent subgroups of other malignancies. In conclusion, ponatinib has proved to be a powerful BCR-ABL inhibitor, which exhibits clinical activity both in BCR-ABL wild-type and mutant CML, including activity against the T315I mutation. Despite previous TKI failure, chronic-phase CML patients can achieve sustained remissions using the novel drug, offering a new therapeutic option in the treatment for CML.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276–283
Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114(27):5426–5435
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al (2012a) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075–2088
Cortes J, Kim D-W, Pinilla-Ibarz J, le Coutre P, Chuah C, Nicolini F, et al (2012b) A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12 month follow up of the PACE trial. Blood 120 ([Abstract 163] presented at ASH meeting 2012 in Atlanta)
Darkow T, Henk HJ, Thomas SK, Feng W, Baladi J-F, Goldberg GA et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):481–496
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26(20):3358–3363
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417
Falco VD, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, et al. (2013) Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab (Internet). 2013 Mar 22 (cited 2013 Apr 29); Available from: http://jcem.endojournals.org/content/early/2013/03/21/jc.2012-2672
Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K et al (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African–American men and women. Pharmacogenetics 13(10):595–606
Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK et al (2011) Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 10(6):1028–1035
Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI et al (2012) Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11(3):690–699
Jain P, Kantarjian H, Cortes J (2013) Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 14(2):127–143
Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260–2270
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12(9):841–851
Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K et al (1990) Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol 74(1):24–29
Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S et al (2005) Response and resistance in 300 patients with BCR-ABL–positive leukemias treated with imatinib in a single center. Cancer 103(8):1659–1669
Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6):2368–2373
Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud J-P, Hayette S (2007) BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res 31(6):865–868
O’Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242–2249
O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401–412
Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M et al (2012) Three novel patient-derived BCR-ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125–E128
Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259
Shah NP, Sawyers CL (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22(47):7389–7395
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 12(24):7374–7379
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541
Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739–3745
von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P et al (2005) A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105(4):1652–1659
Zhou T, Commodore L, Huang W-S, Wang Y, Thomas M, Keats J et al (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1–11
Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer F-D, Hochhaus A et al (2012) Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 157(4):483–492
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wehrle, J., Pahl, H.L., von Bubnoff, N. (2014). Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-54490-3_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54489-7
Online ISBN: 978-3-642-54490-3
eBook Packages: MedicineMedicine (R0)